Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few cells, cancer stem or tumor-initiating cells (TICs) are a severe limitation for the treatment of cancer by conventional therapies. Here, we explored whether human T cells that are redirected via an EpCAM/CD3-bispecific antibody called MT110 can lyse colorectal TICs and prevent tumor growth from TICs. MT110 recognizes EpCAM, a cell adhesion molecule expressed on TICs from diverse human carcinoma, which was recently shown to promote tumor growth through engagement of elements of the wnt pathway. MT110 was highly potent in mediating complete redirected lysis of KRAS-, PI3 kinase- and BRAF-mutated colorectal TICs, as demonstrated in a soft agar assay. In immunodeficient mice, MT110 prevented growth of tumors from a 5,000-fold excess of a minimally tumorigenic TIC dose. T cells engaged by MT110 may provide a potent therapeutic means to eradicate TICs and bulk tumor cells derived thereof.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, EpCAM/CD3 BiTEs eliminated CSCs in colon cancer cell lines and primary CSCs isolated from colon cancer patient samples and blocked CRC xenograft tumor growth [186,187].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Moreover, in colorectal cancer the presence of T cells in tumors correlates with survival of patients [50].”
BackgroundIdentification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998 · cited 1×
“Moreover, independent reports showed expression of EpCAM on colorectal TICs [5,9,47,48], with evidence for a functional role of EpCAM in tumorigenesis [5,20].”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“In order to verify their cancer stem cell phenotype, TICs were analyzed by FACS staining for expression of established surface markers [18], and by using RT-PCR for expression of mRNAs coding for surface and intracellular marker proteins.”
MethodIdentification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523 · cited 1×
“Certain normal epithelial tissues and embryonic stem cells express EpCAM [24–26], but there is evidence to suggest that EpCAM on normal epithelial tissues is largely sequestered while it is accessible on the surface of cancer cells [27,28].”
BackgroundPhenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184 · cited 2×
“, from colorectal and pancreatic tumors, by using antibodies specific for epithelial cell adhesion molecule (EpCAM; also called ESA) [5,6].”
BackgroundTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 2×
“A CD19/CD3-bispecific BiTE antibody called blinatumomab showed high anti-tumor activity in relapsed non-Hodgkin’s lymphoma patients [40], providing clinical proof of concept for the therapeutic principle of BiTE antibodies.”
BackgroundSelf-citationPatrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968 · cited 1×
“Furthermore, the expression of EpCAM and CD44 was shown to track with the tumorigenic phenotype of such cells [5,7– 10].”
BackgroundShmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., Milde, T., St. Clair, R., Baljevic, M., White, I., Jin, D. K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34401 · Cited by 896
Research works printed but not linked: 1
- Kischel R Hausmann S Klinger M Baeuerle PA Kufer P 2009 Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. AACR 2009 poster presentation
Cited by
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
EpCAM and its potential role in tumor-initiating cells
Imrich, S., Hachmeister, M., & Gires, O. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.18953 · Cited by 202
“Thus, combinations of several markers are more reliable to characterize cells as TICs.”
BackgroundInfluentialMolecular Biology of Liver Cancer Stem Cells
Oishi, N., Yamashita, T., & Kaneko, S. (2014) · Liver Cancer · doi:10.1159/000343863 · Cited by 169
Targeting T cells to tumor cells using bispecific antibodies
Frankel, S. R., & Baeuerle, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.029 · Cited by 166
Self-citationT cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Wu, Z., & Cheung, N. V. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.005 · Cited by 150
Recent advances of bispecific antibodies in solid tumors
Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 151
“Another study showed that MT110 eliminated colorectal cancer cells and stem cells [59].”
BackgroundColon cancer stem cells: Potential target for the treatment of colorectal cancer
Gupta, R., Bhatt, L. K., Johnston, T. P., & Prabhavalkar, K. S. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1599660 · Cited by 159
Cioffi, M., Dorado, J., Baeuerle, P. A., & Heeschen, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1270 · Cited by 141
“Unstimulated allogeneic human PBMCs from healthy donors were the source of effector cells that were used at an effector-to-target (E:T) ratio of 5:1, which typically contain between 10% and 20% cytotoxic CD8þ T cells (32).”
BackgroundSelf-citationLin, C., Liao, M.-Y., Lin, W.-W., Wang, Y., Lu, T., & Wu, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.386235 · Cited by 135
“Since EpCAM is overexpressed in tumor and TICs, it is often explored as a potential target for antibody-based therapies, such as adecatumumab, catumaxomab, bispecific EpCAM/CD3 antibody (39-41), and EpCAM antibody-carried nanovesicular drugs (42).”
BackgroundRevisiting the Roles of Pro-Metastatic EpCAM in Cancer
Mohtar, M. A., Syafruddin, S. E., Nasir, S., & Low, T. Y. (2020) · Biomolecules · doi:10.3390/biom10020255 · Cited by 127
“In fact, there is an EpCAM/CD3-bispecific antibody developed, MT110, that functions to redirect T cells to target the stem cells [94,95].”
BackgroundComing-of-Age of Antibodies in Cancer Therapeutics
Ayyar, B. V., Arora, S., & O’Kennedy, R. J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.005 · Cited by 110
Understanding the colon cancer stem cells and perspectives on treatment
Garza-Treviño, E. N., Said‐Fernández, S., & Martínez-Rodríguez, H. G. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0163-7 · Cited by 104
“Cancer stem-like cells (CSLCs) that are resistant to conventional chemotherapy and the bulk cancer cells CSO-SA/OXA micelles Micelle formulation of oxaliplatin (OXA) encapsulated in chitosan vesicle In vitro (HT29 and SW620 line cellular [CD133/CD24]) [87] Garza-Treviño et al.”
BackgroundMethodOberst, M. D., Fuhrmann, S., Mulgrew, K., Amann, M., Cheng, L., Lutterbuese, P., Richman, L., Coats, S., Baeuerle, P. A., & Hammond, S. A. (2014) · mAbs · doi:10.4161/19420862.2014.975660 · Cited by 89
Self-citationMolecular Characterization of Circulating Tumor Cells in Human Metastatic Colorectal Cancer
Barbazán, J., Alonso‐Alconada, L., Muinelo‐Romay, L., Vieito, M., Abalo, A., Alonso‐Nocelo, M., Candamio, S., Gallardo, E., Fernández, B., Abdulkader, I., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040476 · Cited by 93
Boesch, M., Spizzo, G., & Seeber, A. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0289 · Cited by 94
Marquardt, S., Solanki, M., Spitschak, A., Vera, J., & Pützer, B. M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.006 · Cited by 92
The Role of Colorectal Cancer Stem Cells in Metastatic Disease and Therapeutic Response
Anderson, E. C., Hessman, C. J., Levin, T. G., Monroe, M. M., & Wong, M. H. (2011) · Cancers · doi:10.3390/cancers3010319 · Cited by 96
“bi-specific antibody to EpCAM and human CD3 [84], this group was able to eliminate primary human colorectal tumors in a xenograft model, as well as xenografts generated from the HT29 CRC cell line by inducing tumor-specific T-cell cytotoxicity while avoiding apparent toxicity to the host animal [85].”
BackgroundMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For example, EpCAM/CD3 BiTEs eliminated CSCs in colon cancer cell lines and primary CSCs isolated from colon cancer patient samples and blocked CRC xenograft tumor growth [186,187].”
Hamilton, K. E., Noubissi, F. K., Katti, P. S., Hahn, C. M., Davey, S. R., Lundsmith, E. T., Klein-Szanto, A. J., Rhim, A. D., Spiegelman, V. S., & Rustgi, A. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt217 · Cited by 79
Hosseini, S. S., Khalili, S., Baradaran, B., Bidar, N., Shahbazi, M., Mosafer, J., Hashemzaei, M., Mokhtarzadeh, A., & Hamblin, M. R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.058 · Cited by 83
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
Scott, E. M., Duffy, M. R., Freedman, J. D., Fisher, K. D., & Seymour, L. W. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700187 · Cited by 80
Advances in cancer stem cell targeting: How to strike the evil at its root
Pützer, B. M., Solanki, M., & Herchenröder, O. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.013 · Cited by 77
“However, the bi-specific antibody MT110 that binds to EpCAM as well as CD3 led to significant reduction in tumorigenesis, sphere formation of HT-29 cells and patient-derived ovarian CSC [122].”
BackgroundT Cell–Activating Bispecific Antibodies in Cancer Therapy
Trabolsi, A., Arumov, A., & Schatz, J. H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900496 · Cited by 70
“In phase I, however, dosage escalation, unfortunately, was not possible because of significant adverse events (AEs); 1 out of 65 patients had an unconfirmed partial response (44).”
MethodInfluentialUtilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Stieglmaier, J., Benjamin, J., & Nagorsen, D. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1041373 · Cited by 73
“A Phase I study of the anti-EpCAM BiTE AMG110 (MT-110, NCT00635596) has recently completed recruitment, and analysis is ongoing [21-23].”
BackgroundCancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source
Ruiu, R., Tarone, L., Rolih, V., Barutello, G., Bolli, E., Riccardo, F., Cavallo, F., & Conti, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.008 · Cited by 53
Monoclonal Antibodies Against Human Cancer Stem Cells
Naujokat, C. (2014) · Immunotherapy · doi:10.2217/imt.14.4 · Cited by 50
Zhang, P., Shi, B., Gao, H., Jiang, H., Kong, J., Yan, J., Pan, X., Li, K., Zhang, P., Yao, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1497-4 · Cited by 49
A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor
Ma, H., Wang, H., Sové, R. J., Jafarnejad, M., Tsai, C.-H., Wang, J., Giragossian, C., & Popel, A. S. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00450-3 · Cited by 50
The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture
Hoh, A., Dewerth, A., Vogt, F., Wenz, J., Baeuerle, P. A., Warmann, S. W., Fuchs, J., & Armeanu–Ebinger, S. (2012) · Liver International · doi:10.1111/liv.12011 · Cited by 48
“MT110 is currently tested in a phase I trial and may help to improve immune therapy of various solid tumours including liver malignancies (24).”
BackgroundSelf-citationT cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
Lin, Y., & Wang, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02867-6 · Cited by 44
Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells
Ahmed, M., Chaudhari, K., Babaei‐Jadidi, R., Dekker, L. V., & Nateri, A. S. (2017) · Stem Cells · doi:10.1002/stem.2579 · Cited by 45
Prasad, S., Gaedicke, S., Machein, M. R., Mittler, G., Braun, F., Hettich, M., Firat, E., Klingner, K., Schüler, J. B., Wider, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2415 · Cited by 41
“In these studies, EpCAM CD3 bsAbs were effective against CSCs, including CSCs that coexpress EpCAM and CD133 (33–35).”
BackgroundEpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale
Herreros‐Pomares, A., Aguilar-Gallardo, C., Fariñas, S. C., Sirera, R., Lewintre, E. J., & Camps, C. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.006 · Cited by 40
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives
Vitale, S. G., Laganà, A. S., Capriglione, S., Angioli, R., Rosa, V. L. L., Lopez, S., Valenti, G., Sapia, F., Sarpietro, G., Butticè, S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051100 · Cited by 39
“Accordingly, differences in the influence of EpCAM-specific antibodies on the proliferation of EpCAM-positive cells have recently been demonstrated [73] and must be taken into consideration for future developments.”
BackgroundTakai, A., Dang, H. T., Oishi, N., Khatib, S. A., Martin, S. P., Dominguez, D. A., Luo, J., Bagni, R., Wu, X., Powell, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3015 · Cited by 32
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
Armeanu–Ebinger, S., Hoh, A., Wenz, J., & Fuchs, J. (2013) · OncoImmunology · doi:10.4161/onci.22620 · Cited by 34
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 34
Stamova, S., Feldmann, A., Cartellieri, M., Arndt, C., Koristka, S., Apel, F., Wehner, R., Schmitz, M., Bornhäuser, M., Bonin, M. V., et al. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2011.12.042 · Cited by 32
Peng, L., Oberst, M. D., Huang, J., Brohawn, P. Z., Morehouse, C., Lekstrom, K. J., Baeuerle, P. A., Wu, H., Yao, Y., Coats, S. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036412 · Cited by 32
“Furthermore, BiTE antibodies promote in vivo tumor regression in numerous pre-clinical animal models [16, 31, 32, 33, 34, 35, 36] and have shown signs of clinical benefit in patients with cancer [37, 38, 39] .”
BackgroundSelf-citationZhang, T., Lv, J., Tan, Z., Wang, B., Warden, A. R., Li, Y., Jiang, H., Li, H., & Ding, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01571 · Cited by 31
“Recent research confirms that therapeutic strategies, using EpCAM/CD3bispecific antibody, are significantly effective in tumor elimination (44).”
BackgroundBispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.
Huang, Q., Cai, W.-Q., Han, Z.-W., Wang, M., Zhou, Y., Cheng, J.-T., Zhang, Y., Wang, Y., Xin, Q., Wang, X.-W., et al. (2021) · PubMed · Cited by 33
Fujiwara, D., Kato, K., Nohara, S., Iwanuma, Y., & Kajiyama, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.008 · Cited by 25
“In this experiment, expression of CD44, CD133, and CD338 was weaker in 3-D-cultured cells than in 2-D-cultured cells, but expression of CD318 and CD326 did not differ.”
InfluentialMathan, S. V., & Singh, R. P. (2025) · Cancers · doi:10.3390/cancers17132100 · Cited by 25
Update on immune‐based therapy strategies targeting cancer stem cells
Izadpanah, A., Mohammadkhani, N., Masoudnia, M., Ghasemzad, M., Saeedian, A., Mehdizadeh, H., Poorebrahim, M., & Ebrahimi, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6520 · Cited by 26
Han, H., Ma, J., Zhang, K., Li, W., Liu, C., ZHANG, Y., Zhang, G., Ma, P., WANG, L., Zhang, G., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2663 · Cited by 25
A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer
Barbazán, J., Vieito, M., Abalo, A., Alonso‐Alconada, L., Muinelo‐Romay, L., Alonso‐Nocelo, M., León‐Mateos, L., Candamio, S., Gallardo, E., Anido, U., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01544.x · Cited by 23
“Finally, antibodies against EpCAM can efficiently target colorectal tumour-initiating cells [16], conferring a considerable value Fig.”
BackgroundTargeting Cancer Stem Cells with Defined Compounds and Drugs
Naujokata, C., & Laufer, S. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.01.7 · Cited by 27
“2 (anti-CD47) AML SCs, bladder CSCs Preclinical [342] [343] Monoclonal antibody 7G3, CSL362 (anti-CD123) AML SCs Phase I: CSL362, AML [347] Bispecific antibody, bifunctional MT110 (anti-EpCAM/ anti-CD3) Colon CSCs, pancreatic CSCs Phase I, advanced solid tumors [352] [353] Bispecific antibody, trifunctional Catumaxoma…”
BackgroundAntitumor Activities of PSMA×CD3 Diabodies by Redirected T-cell Lysis of Prostate Cancer Cells
Baum, V., Bühler, P., Gierschner, D., Herchenbach, D., Fiala, G. J., Schamel, W. W. A., Wolf, P., & Elsässer‐Beile, U. (2012) · Immunotherapy · doi:10.2217/imt.12.136 · Cited by 24
Microscopy Method to Compare Cyst Nematode Infection of Different Plant Species
Kooliyottil, R., Dandurand, L., Govindan, B. N., & Knudsen, G. R. (2016) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2016.76029 · Cited by 22
“Because of its extremely stable fluorescence, PKH26 is useful when labeled cells are to be followed for extended periods as demonstrated by the four-week retention time of PKH26 in mammalian cells [10].”
BackgroundMulti-Specific Antibodies for Cancer Immunotherapy
Jachimowicz, R. D., Borchmann, S., & Rothe, A. (2014) · BioDrugs · doi:10.1007/s40259-014-0091-4 · Cited by 21
“Furthermore, high doses of MT110 led to regression of HT-29-derived established subcutaneous tumors [21].”
BackgroundRecent developments in antibody derivatives against colorectal cancer; A review
Ghani, S., Bahrami, S., Rafiee, B., Eyvazi, S., Yarian, F., Ahangarzadeh, S., Khalili, S., Shahzamani, K., Jafarisani, M., Bandehpour, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118791 · Cited by 20
Groth, A., Salnikov, A. V., Ottinger, S., Gladkich, J., Liu, L., Kallifatidis, G., Salnikova, O. V., Ryschich, E., Giese, N. A., Giese, T., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2767 · Cited by 22
“Quite similarly, Herrmann and colleagues (36) showed that EpCAMxCD3-mediated engaging of human T cells eliminates colorectal tumor-initiating cells.”
Shen, J., Qian, N., Xu, G., Dou, X., An, Y., Yang, C., Liu, Y., Liu, Y., Pan, X., Wang, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112424 · Cited by 17
Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Dicato, M. A., & Diederich, M. F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505124037 · Cited by 17
Colorectal Cancer Stem Cells and Targeted Agents
Zhao, H., Han, R., Wang, Z., Xian, J., & Bai, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122763 · Cited by 18
Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery
Andrews, T. E., Wang, D., & Harki, D. A. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0075-1 · Cited by 20
“MT110 has been shown to have high antitumor activity in various animal models [159, 161] and is capable of completely eliminating colorectal CSCs in cell culture and in animal models [162].”
BackgroundSkidan, I. N., & Steiniger, S. C. J. (2014) · PubMed · Cited by 21
Targeting Human Cancer Stem Cells with Monoclonal Antibodies
Naujokat, C. (2012) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.s5-007 · Cited by 15
Advances in Bispecific Antibodies Engineering: Novel Concepts for Immunotherapies
Spasevska, I. (2015) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000243 · Cited by 14
“In preclinical studies MT110 has demonstrated a highly efficient elimination of colorectal and pancreatic tumor-initiating cells [54,55].”
BackgroundTatari, N., Zhang, X., Chafe, S. C., McKenna, D., Lawson, K. A., Subapanditha, M., Shaikh, M. V., Seyfrid, M., Savage, N. J., Venugopal, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.905768 · Cited by 12
Development and clinical application of bispecific antibody in the treatment of colorectal cancer
Balibegloo, M., & Rezaei, N. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1783249 · Cited by 11
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management
Chen, J., Ma, N., Chen, B., Huang, Y. C., Li, J., Li, J., Chen, Z., Wang, P., Ran, B., Yang, J., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104604 · Cited by 10
Alqarni, A., Jasim, S. A., Altalbawy, F. M. A., Kaur, H., Kaur, I., Rodriguez‐Benites, C., Deorari, M., Alwaily, E. R., Al‐Ani, A. M., & Redhee, A. H. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23719 · Cited by 9
Breast cancer immunotherapy: a comprehensive review
Keshavarz, S., Wall, J. R., Keshavarz, S., Vojoudi, E., & Jafari-Shakib, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01177-z · Cited by 9
A T cell redirection platform for co-targeting dual antigens on solid tumors
Enderle, L., Shalaby, K. H., Gorelik, M., Weiss, A., Blazer, L. L., Paduch, M., Cardarelli, L., Kossiakoff, A. A., Adams, J., & Sidhu, S. S. (2021) · mAbs · doi:10.1080/19420862.2021.1933690 · Cited by 9
Therapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00032-1 · Cited by 8
Bispecific Antibodies in Colorectal Cancer Therapy: Recent Insights and Emerging Concepts
Ghalamfarsa, F., Khatami, S. H., Vakili, O., Taheri‐Anganeh, M., Tajbakhsh, A., Savardashtaki, A., Fazli, Y., Uonaki, L. R., Shabaninejad, Z., Movahedpour, A., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0107 · Cited by 7
Therapeutic Antibodies and Immunologic Conjugates
Dobrenkov, K., & Cheung, N. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00030-x · Cited by 5
Soroush, A., Shahhosseini, R., Ghavamikia, N., Hjazi, A. M., Roudaki, S., KhalatbariLimaki, M., Mirbolouk, M., Pakmehr, S., & Karimi, P. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4055 · Cited by 3
Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives
Ismail, M., Al‐Gizey, N., Al-Najjar, E., Alabed, Z., Mustafa, N., Hamdaneh, Y., & Esmail, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1927829 · Cited by 1
Woisetschläger, M., Rüker, F., Mudde, G. C., Wozniak‐Knopp, G., Bauer, A., & Himmler, G. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch39 · Cited by 1
Targeting Cancer Stem Cells and the Tumor Microenvironment
Turdo, A., Todaro, M., & Stassi, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_16 · Cited by 2
Cytokine Release Syndrome: An Overview on its Features and Management
Shreshtha, S., Kumar, P., Sharma, P. A., & Sharma, R. (2019) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.13.1.14 · Cited by 2
Jacome, A. A. D. A., Peixoto, R. D., Gil, M. V., Ominelli, J., Prolla, G., Dienstmann, R., & Eng, C. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2108700 · Cited by 1
“[106,107], but no clinical trials are currently ongoing.”
BackgroundHerreros‐Pomares, A. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/137036 · Cited by 1
Signaling Pathways in Cancer Stem Cells: Therapeutic Implications
Pastò, A., Amadori, A., & Indraccolo, S. (2012) · Springer eBooks · doi:10.1007/978-94-007-2900-1_1
A nanoliposome-based drug delivery system for cancer
Lin, J. (2013)
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
Enhancing the potency and water solubility of the sesquiterpene lactone parthenolide
Andrews, T. E. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Development of T cell based therapeutic strategies for childhood cancer neuroblastoma
Patel, A. (2017) · UCL Discovery (University College London) · Cited by 1
Cioffi, M., Dorado, J., Baeuerle, P. A., & Heeschen, C. (2023) · doi:10.1158/1078-0432.c.6519911
Self-citationCioffi, M., Dorado, J., Baeuerle, P. A., & Heeschen, C. (2023) · doi:10.1158/1078-0432.c.6519911.v1
Self-citationSYNTHESIS AND EVALUATION OF PARTHENOLIDE ANALOGUES: CHEMICAL PROBES AND THERAPEUTIC AGENTS
Wang, D. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Metadata
- Authors
- Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., & Münz, M.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Baeuerle, Patrick A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-18
- Volume
- 5
- Issue
- 10
- Pages
- e13474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2956687
- OpenAlex
- W2024837280
- Cited by
- 85
- References
- 50
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 3 · 2017: 7 · 2016: 2 · 2015: 7 · 2014: 8 · 2013: 10 · 2012: 13
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- cancer stem cells, EpCAM, CD3, bispecific antibodies, T cell redirection, adoptive T cell therapy, tumor cell lysis, KRAS mutation, BRAF mutation, Wnt signaling
- MeSH terms
- Epithelial Cell Adhesion Molecule, Animals, Antigens, Neoplasm, Flow Cytometry, Humans, T-Lymphocytes, Colorectal Neoplasms, Cell Adhesion Molecules, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Antibodies, Bispecific, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.